
Season's Greetings
TWINCORE wishes you happy holidays and a successful new year

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

TWINCORE wishes you happy holidays and a successful new year

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases

€100,000 from the German Society for Parkinson's Disease and Movement Disorders
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Strunz B, Zhan Q, Khera T, Hengst J, Jankovic M, Deterding K, Niehrs A, Cornberg M, Xu C, Wedemeyer H, Björkström N
Heinrich S, Ten Thoren P, Behrendt P, Hagenah J, Wedemeyer H, Potthoff A, Maasoumy B
Sousa C, Terroba-Navajas P, Tzartos J, Orešković I, Pučić-Baković M, Lauc G, Bartsch Y, Kaminski H, Lünemann J
The project investigates the immune response of the central nervous system in viral infections, in particular the role of type I IFN, microglia and monocytes in the development of encephalitis and their influence on seizures and hippocampal damage.
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.
There are currently no events.

